Neuroprotection in Patients Undergoing Aortic Valve Replacement

NACompletedINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Aortic StenosisBrain InfarctionCerebrovascular AccidentStroke
Interventions
DEVICE

Embol-X Embolic Protection Device

per the manufacturer's instructions for use (IFU).

DEVICE

CardioGard Cannula

CardioGard Cannula, per the manufacturer's instructions for use (IFU).

Trial Locations (18)

10032

Columbia University Medical Center, New York

10467

Montefiore Einstein Heart Center, The Bronx

19104

University of Pennsylvania, Philadelphia

20814

NIH Heart Center at Suburban Hospital, Bethesda

21201

University of Maryland, Baltimore

22908

University of Virginia, Charlottesville

27710

Duke University, Durham

28801

Mission Hospital, Asheville

30308

Emory University, Atlanta

43210

Ohio State University, Columbus

44195

Cleveland Clinic Foundation, Cleveland

75093

Baylor Research Institute, Plano

90033

University of Southern California, Los Angeles

03766

Dartmouth-Hitchcock Medical Center, Lebanon

T6G2B7

University of Alberta Hospital, Edmonton

M5B 1W8

Toronto General Hospital, Toronto

H1T 1C8

Montreal Heart Institute, Montreal

G1V 4G5

Institut Universitaire de Cardiologie de Quebec (Hopital Laval), Québec

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT02389894 - Neuroprotection in Patients Undergoing Aortic Valve Replacement | Biotech Hunter | Biotech Hunter